Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

ADHD Drug Ritalin Has No Effect on Primate Prefrontal Cortex

By Society for Neuroscience | February 25, 2019

Figure 2a. Location of chronically implanted multielectrode Utah array within the left caudal lateral prefrontal cortex. The shaded pink area roughly represents area 8A in the macaque brain. The blue square represents implant location. P: principal sulcus. AS: arcuate sulcus superior. AI: arcuate sulcus inferior. Tremblay et al., eNeuro (2019)

In contrast to studies of mice and rats, new research published in eNeuro investigating the effect of methylphenidate (Ritalin) on neuronal activity in monkeys has found no effect of the drug on the prefrontal cortex. The study leaves open the question of how and why Ritalin improves attention in humans.

Julio Martinez-Trujillo and colleagues refute their hypothesis the caudal prefrontal cortex– a brain region critical for attention — is Ritalin’s main site of action in the brain. To arrive at this conclusion, the researchers recorded large populations of neurons in this brain region as two male macaque monkeys performed a demanding visual attention task. The team did not observe any differences in neuronal activity after administration of the drug compared to a placebo, even at doses that improved the monkeys’ performance on the task.

These negative results do not rule out other regions of the prefrontal cortex as possible sources of Ritalin’s action in the brain. In addition, they highlight the difficulty of translating preclinical research from rodents to nonhuman primates and call for improved collaboration between scientists investigating common questions using different animal models.


Filed Under: Neurological Disease

 

Related Articles Read More >

Astellas Pharma in the Drug Discovery & Development Pharma 50
FDA places clinical hold on Astellas clinical trial focused on Pompe disease
FDA
FDA launches 5-year initiative for rare neurodegenerative diseases 
Biogen in the Drug Discovery & Development Pharma 50
Biogen halts observational post-marketing study of aducanumab
Amylyx
Inside Canada’s approval of Amylyx’s ALS drug Albrioza

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50